User:Tkadm30/Notebook/Endocannabinoids/Anandamide: Difference between revisions
From OpenWetWare
Line 23: | Line 23: | ||
#Paper3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533417/ | #Paper3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533417/ | ||
//Diuretic Effects of Cannabinoids | //Diuretic Effects of Cannabinoids | ||
#Paper4 https://www.ncbi.nlm.nih.gov/pubmed/18832445 | |||
//The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway. | |||
</biblio> | </biblio> |
Revision as of 04:06, 17 April 2017
Intracellular anandamide trafficking as a promoter of neurogenesis acting through presynaptic CB1/FABP binding
The maturation and differentiation of neural stem cells via fatty-acid binding proteins (FABPs) signaling may require anandamide as a promoter of CB1-dependent neurogenesis. [1]
Hippocampal neurogenesis with synaptogenic promoter (DHA) is induced by intracellular and presynaptic CB1 receptor binding to anandamide. [2]
Notes
- Allosteric activation of PPAR-RXR heterodimer by anandamide (CB1/TRPV1 receptors) facilitate hippocampal neurogenesis.
- Intracellular FABP5 expression result in anandamide trafficking of heteromeric CB1 receptor.
- Adenosine antagonism potentiate organized trafficking of anandamide via heteromization of CB1 receptor.
- Anandamide biosynthesis enhances diuresis. [3]
See also
References
-
Type-1 (CB1) Cannabinoid Receptor Promotes Neuronal Differentiation and Maturation of Neural Stem Cells
-
Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide.
-
Diuretic Effects of Cannabinoids
-
The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway.